Literature DB >> 662080

Prolactin suppression by serotonin antagonists in man: further evidence for serotoninergic control of prolactin secretion.

C Ferrari, R Caldara, M Romussi, P Rampini, P Telloli, S Zaatar, G Curtarelli.   

Abstract

To further investigate the role of serotonin in human prolactin (Prl) secretion, serotonin antagonists have been administered to healthy volunteers in basal conditions and after pretreatment with the selective blocker of dopamine receptors, pimozide (Pim). Highly significant falls (p less than 0.001) in serum Prl were observed at 120, 180, and 240 min following the oral administration of metergoline (Met) (4 mg; N = 34) and methysergide (Meth) (3 mg; N = 20) in comparison with placebo. No significant difference was found in the degree of Prl suppression induced by these two serotonin antagonists and by hte dopaminergic drug bromocriptine (Br) (2.5 mg; N = 20). After Pim pretreatment (1 mg every 6 h for 7 days) the elevated serum Prl levels were reduced to 27.1% +/- 8.1 (SEM) of basal after Met and to 54.5% +/- 8.9 after Meth administration (N = 5 for each study). It is concluded that Met and Meth inhibit Prl secretion by mechanisms which are not or only partially related to dopaminergic receptors. These data are consistent with a stimulatory role for serotonin in human Prl release.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 662080     DOI: 10.1159/000122753

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  9 in total

1.  Intolerance of bromocriptine: is metergoline a satisfactory alternative?

Authors:  I F Casson; B A Walker; L J Hipkin; P E Belchetz
Journal:  Br Med J (Clin Res Ed)       Date:  1985-06-15

2.  Inhibition of cimetidine-induced hyperprolactinemia by pretreatment with metergoline.

Authors:  M Iodice; G Lombardi; A P Tommaselli; R Rossi; M Minozzi
Journal:  J Endocrinol Invest       Date:  1981 Jan-Mar       Impact factor: 4.256

3.  Metergoline versus bromocriptine in the prevention of puerperal lactation. A double-blind clinical trial.

Authors:  F Scapin; S Buonaccorsi; G Tronconi; G Pellicciotta; A E Pontiroli
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

4.  Improved oral glucose tolerance following antiserotonin treatment in patients with chemical diabetes.

Authors:  C Ferrari; C Barbieri; R Caldara; V Magnoni; G P Testori; M Romussi
Journal:  Eur J Clin Pharmacol       Date:  1979-07       Impact factor: 2.953

5.  Effect of two antiserotoninergic drugs, methysergide and metergoline, on gastric acid secretion and gastrin release in healthy man.

Authors:  R Caldara; C Ferrari; C Barbieri; M Romussi; P Rampini; P Telloli
Journal:  Eur J Clin Pharmacol       Date:  1980-01       Impact factor: 2.953

6.  Inhibitory effect of ritanserin on the 5-hydroxytryptophan-mediated cortisol, ACTH and prolactin secretion in humans.

Authors:  M A Lee; J F Nash; M Barnes; H Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

7.  Effect of dihydroergokryptine administration on serum prolactin and growth hormone levels in normal, hyperprolactinaemic and acromegalic subjects: evidence of potent and long-lasting pituitary dopamine receptor stimulation.

Authors:  C Ferrari; P Rampini; A Paracchi; M Boghen; F Mailland
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  Metergoline abolishes the prolactin response to buspirone.

Authors:  C A Gregory; I M Anderson; P J Cowen
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

9.  Effect of metergoline on serum prolactin stimulated by TRH.

Authors:  F Iannotta; G Gadaleta; C Pollini; M P Vettaro
Journal:  J Endocrinol Invest       Date:  1980 Jul-Sep       Impact factor: 4.256

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.